Search results
Showing 801 to 850 of 1865 results for do not do
NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,
you may be offered regular scans to check for breast cancer. Most women who do develop breast cancer can be successfully treated. Your...
Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.
Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS191Show all sections
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Genicular artery embolisation for pain from knee osteoarthritis (HTG595)
Evidence-based recommendations on genicular artery embolisation for pain from knee osteoarthritis. This involves inserting a tube through an artery in the groin into the genicular artery, and injecting tiny particles through it to block new blood vessels.
View recommendations for HTG595Show all sections
Direct C1 lateral mass screw for cervical spine stabilisation (HTG92)
Evidence-based recommendations on direct C1 lateral mass screw for cervical spine stabilisation. This involves using screws to fix the bones together to treat atlantoaxial fusion in the neck.
View recommendations for HTG92Show all sections
Sections for HTG92
Endoscopic injection of bulking agents for gastro-oesophageal reflux disease (HTG28)
Evidence-based recommendations on endoscopic injection of bulking agents for gastro-oesophageal reflux disease. This involves injecting a filler into the junction using a catheter to make the entry to the stomach narrower, so that the contents of the stomach cannot pass back.
View recommendations for HTG28Show all sections
Sections for HTG28
High-intensity focused ultrasound for symptomatic benign thyroid nodules (HTG504)
Evidence-based recommendations on high-intensity focused ultrasound for symptomatic benign thyroid nodules in adults. This involves using heat made by high-frequency sound waves to destroy the nodule.
View recommendations for HTG504Show all sections
Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. This involves replacing the 2 lower chambers of the heart with a mechanical device to improve circulation until heart transplantation.
NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer .
Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Transcranial magnetic stimulation for auditory hallucinations (HTG555)
Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.
View recommendations for HTG555Show all sections
Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (HTG654)
Evidence-based recommendations on laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. This involves placing a ring of beads outside of the food pipe, just above the stomach. Magnets inside the beads hold them together to keep the food pipe closed but are weak enough to move apart to allow food or liquid to be swallowed. The aim is to prevent acid reflux.
View recommendations for HTG654Show all sections
Superficial venous arterialisation for chronic limb threatening ischaemia (HTG637)
Evidence-based recommendations on superficial venous arterialisation for chronic limb threatening ischaemia in adults. This involves joining an artery in the lower leg to a large vein to divert blood flow through the vein towards the foot, bypassing the blocked arteries.
View recommendations for HTG637Show all sections
Training and development opportunities at NICE
Training and development opportunities at NICE
Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.
View recommendations for HTG470Show all sections
Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Endobronchial nerve ablation for chronic obstructive pulmonary disease (HTG604)
Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.
View recommendations for HTG604Show all sections
Extracorporeal whole liver perfusion for acute liver failure (HTG573)
Evidence-based recommendations on extracorporeal whole liver perfusion for acute liver failure. This involves blood being diverted to a whole liver (perfusion) outside the body and returned to the patient.
View recommendations for HTG573Show all sections
Implanted vagus nerve stimulation for treatment-resistant depression (HTG551)
Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under the skin of the chest and connecting it by wires to the vagus nerve.
View recommendations for HTG551Show all sections
Mini/micro screw implantation for orthodontic anchorage (HTG152)
Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.
View recommendations for HTG152Show all sections
Sections for HTG152
Nerve transfer to partially restore upper limb function in tetraplegia (HTG466)
Evidence-based recommendations on nerve transfer to partially restore upper limb function in people with tetraplegia. This involves connecting an undamaged, functioning, but non-essential nerve near the injury to the damaged essential nerve.
View recommendations for HTG466Show all sections
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.
We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.